{"id":"NCT02020369","sponsor":"rEVO Biologics","briefTitle":"Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors","officialTitle":"A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-07","completion":"2015-08","firstPosted":"2013-12-24","resultsPosted":"2017-06-14","lastUpdate":"2017-06-14"},"enrollment":27,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A With Inhibitors","Hemophilia B With Inhibitors"],"interventions":[{"type":"BIOLOGICAL","name":"Coagulation Factor VIIa (Recombinant)","otherNames":[]}],"arms":[{"label":"FVIIa: 75 µg/kg first, then 225 µg/kg","type":"EXPERIMENTAL"},{"label":"FVIIa: 225 µg/kg first, then 75 µg/kg","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX","primaryOutcome":{"measure":"Proportion of Successfully Treated Mild/Moderate Bleeding Episodes","timeFrame":"12 hours after first administration of study drug","effectByArm":[{"arm":"FVIIa 75 µg/kg","deltaMin":0.849,"sd":null},{"arm":"FVIIa 225µg/kg","deltaMin":0.932,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":17,"countries":["United States","Belarus","Bulgaria","Georgia","Israel","Poland","Romania","Russia","Ukraine","United Kingdom"]},"refs":{"pmids":["40765904","40674256"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":25},"commonTop":["Nasopharyngitis","Headache"]}}